Dysfunctional uterine bleeding
Aboubakr Elnashar
Benha university, Egypt
Aboubakr Elnashar
Define
DUB:
Any abnormal uterine bleeding in absence of
pregnancy, genital tract pathology, or systemic
disease
Menorrhagia;
commonest symptom
DUB: 50-60%
15-20% of gynaecological referrals to Hospital
Excessive blood loss:
>80mL are clinically meaningless
If periods are reported as unacceptably heavy. then
they are!
Aboubakr Elnashar
CLINICAL TYPES
Polymenorrhoea: frequent (<21 d) menstruation, at
regular intervals
Menorrhagia: Excessive & / or prolonged menstruation,
at regular intervals
Metrorrhagia: Excessive & / or prolonged menstruation
at irregular intervals.
Menometrorrhagia: both.
Intermenstual bleeding: episodes of uterine bleeding
between regular menstruations
Hypomenorrhoea: scanty menstruation.
Oligomenorrhea: infrequent menstruation (>35 d)
Aboubakr Elnashar
Aetiology
unknown.
Mechanisms
1. Abnormal PG ratios (+ other inflammatory
mediators) favoring VD and platelet non-
aggregation.
2. Excessive fibrinolysis.
3. Defects in expression/function of matrix
metalloproteinases (MMPs), vascular growth
factors, and endothelins.
4. Aberrant steroid receptor function.
5. Defects in the endomyometrial junctional zone.
Aboubakr Elnashar
Diagnosis
Symptoms
1. Heavy and/or prolonged vaginal bleeding (with
clots and flooding):
2. Irregular, heavy periods usually occur at the
extremes of reproductive life (post-menarche
and peri-menopausal).
3. ± dysmenorrhoea.
4. Systemic symptoms of anaemia and disruption
of life due to bleeding.
5. A smear history and contraceptive use are vital
information.
Totally irregular bleeding, IMB. or PCB:
prompt a search for cervical or endometrial
pathology. Aboubakr Elnashar
Clinical signs
1. Anaemia.
2. Abdomino-pelvic examination:
usually normal.
If the uterus is significantly enlarged. fibroids are
likely.
Aboubakr Elnashar
Differential diagnosis
1. Submucous fibroids.
2. Adenomyosis.
3. Endometrial polyps, hyperplasia, or cancer.
4. Very rarely
hypothyroidism or
coagulation defects.
Aboubakr Elnashar
Investigations
1. Pregnancy should always be considered and excluded.
2. CBC (Hb + MCV).
3. Not a routine
a. Ferritin, TFT s, and clotting screens:
investigations-only consider if clinically indicated.
b. Cervical smears: not done opportunistically if smear history
normal.
c. STI screen including Chlamydia.
Aboubakr Elnashar
Testing for coagulation disorders (von Willebrand’s disease)
1. HMB since menarche adolescents
2. Personal or family history suggesting a coagulation
disorder.
Prothrombin time, Partial thrmoplastin time, Bleeding time,
Platelets, Von Willebrand factor with the ristocetin cofactor
assay {the single best screening test for the disease. This
prevents false-negative results}
 Prolactin & TSH: especially in adolescents
Aboubakr Elnashar
4. <45yrs
The risk of endometrial pathology is very small: No
further investigation: treat and await clinical
response.
Aboubakr Elnashar
5. If >45yrs
risk factors for endometrial disease, or
no clinical response:
1. TVS US
 endometrial polyps
fibroids
measuring endometrial thickness.
The risk of endometrial pathology with a normal
TVS USS is small, but it may be less accurate
during menstruation
Aboubakr Elnashar
2. Pipelle endometrial biopsy
Indication: erratic bleeding in
women >45yrs
To exclude hyperplasia or
cancer
Aboubakr Elnashar
3. Hysteroscopy and biopsy
• Indication
1. Erratic bleeding in a woman >45yrs if USS
reveals focal pathology. e.g. polyp, or is unable
to assess the whole endometrium,
2. biopsy is inadequate
3. bleeding is persistent or repeated.
Aboubakr Elnashar
Management
Regular DUB
1. Mirena IUCD
•Releases measured doses of levonorgestrel into the
endometrial cavity for 5yrs inducing an atrophic
endometrium.
•Effects:
Blood loss dec by up to 90%
30% will be amenorrhoeic at 12mths.
major dec in number of hysterectomies.
Provides contraception.
•Side effects:
insertional issues
irregular PV bleeding for first 4-6mths (usually abates)
progestagenic side effects: rare {minimal systemic
absorption}. Aboubakr Elnashar
2. Antifibrinolytics:
tranexamic acid
•1g tds days 1-4
•40% dec in loss
•Safe, non-hormonal, non-contraceptive
•Side effects
leg cramps
minor GI upset
•Caution in cardiac disease.
The majority of women will respond to medical
therapy, especially tranexamic ± mefenamic add.
Aboubakr Elnashar
3. NSAIDS:
mefenamic acid
•500mg tds days 1-5
•20-30% dec in loss
•significant dec in dysmenorrhoea
•Safe, non-hormonal contraceptive.
•Side effects
GI upset including ulceration.
renal impairment
•Caution:
Asthmatic
CV disease
renal impairment
peptic ulcer.
Aboubakr Elnashar
4. COCP:
•20-30% dec loss
•improvement in dysmenorrhoea
•provides contraception
•Side effects
BTB
Headache
Wt gain
Aboubakr Elnashar
•Contraindications
1. Breast cancer
2. Breast feeding, postpartum less than 1 month
3. Cirrhosis Severe
4. DVT/PE
5. DM: nephropathy, retinopathy,
6. GB disease
7. Headache: Migraine with aura
8. Hypertension
9. Liver tumors: adenoma, malignancy
10.Multiple risk factors for arterial vas Dis
11.Smoking +above 35 y
12.SLE
13.Viral hepatitis: acute
14.Drug interaction: Anticonvulsant, Rifampicin,Aboubakr Elnashar
5. Oral progestagens:
no benefit in regular menorrhagia
other than-short term continuous treatment to stop
bleeding.
Aboubakr Elnashar
Irregular DUB
1. Mirena IUCD:
as above.
2. Tranexamic
3. mefenamic acid
useful to dec loss during periods.
4. COCP
regulate an irregular cycle
safe up to the menopause if no other cardiovascular
risk factors.
Aboubakr Elnashar
4. Progestagen
•Cyclical (days 5-26)
•Norethisterone
5mg tds or
medroxyprogesterone acetate
5-10 mg tds
•Regulates cycle. but little evidence to suggest dec
in loss
•Side effects
Bloating
headache.
Aboubakr Elnashar
5. further medical treatment
Indications
1. First-line therapy has failed
2. Very anaemic women, bleeding continuously.
having their life disrupted
3. Cautions or contraindications to surgery.
a. GnRH analogues
•Achieve amenorrhoea quickly by inducing a
medical menopausal state
•Side effects
vasomotor symptoms
•use limited to 6-12mths maximum {bone loss}.
Aboubakr Elnashar
b. High-dose progestagens:
•medroxyprogesterone acetate
10mg tds continuously
•induce amenorrhoea.
•may be time-limited due to side effects.
Danazol and ethamsylate: no longer indicated.
Aboubakr Elnashar
Surgical management
Indications
1. Failure to respond to medical management
2. Women have completed her family
Aboubakr Elnashar
1. Endometrial ablation
 Destruction of the endometrium
down to the basalis layer
Effective for most women
Methods:
1. Hysteroscopic resection, or
rollerball ablation
now used much less often {operative
complications}
2. New
A. Microwave (MEA).
B. Thermal balloon (Thermachoice).
C. Novasure (electrical impedance).
Aboubakr Elnashar
Therma Choice: Heating element within the balloon
(Neuwirth et al 1994)
Aboubakr Elnashar
Nova sure: The bipolar radio frequency wire mesh over
a triangular frame (Cooper et al 2002)
Aboubakr Elnashar
Microwave endometrial
ablation (Bain et al., 2002)
MEA
Aboubakr Elnashar
Results
•less effective
if the endometrial cavity is >10cm.
•in normal size cavities:
80-90%: significantly improved.
30%: amenorrhoeic.
20%: need a second procedure by 5yrs.
Risk: Small
bleeding, infection, uterine perforation, and failed
procedure.
very safe and straight­forward
Carried out under GA but may occasionally be
done under cervical block.
Aboubakr Elnashar
2. Hysterectomy
The only guaranteed cure for DUB
Compared to ablation
higher morbidity
longer recovery
financial costs
Complications
Haemorrhage
Infection
bladder, ureteric, or bowel injury «1%).
Death is extremely rare.
Long-term satisfaction rates
very high and regardless of method most women
report improved sexual function
Aboubakr Elnashar
Aboubakr Elnashar
Aboubakr Elnashar
Thank you

More Related Content

PPT
dysfunctional uterine bleeding
PPTX
Uterine fibroids
PPTX
Abnormal Uterine Bleeding
PPTX
Menstrual cycle
PPTX
functions of micronutrients.pptx
PPTX
Approach to cough
PPTX
PELVIC INFLAMMATORY DISEASE (PID)
PPTX
Rupture of the uterus
dysfunctional uterine bleeding
Uterine fibroids
Abnormal Uterine Bleeding
Menstrual cycle
functions of micronutrients.pptx
Approach to cough
PELVIC INFLAMMATORY DISEASE (PID)
Rupture of the uterus

What's hot (20)

PPTX
Cervical erosion
PPT
Amenorrhea
PPTX
PPTX
Amenorrhea
PPTX
Preterm labour
PDF
Premenstrual syndrome
PPTX
Genital tuberculosis
PPTX
Disorders of menstruation
PPTX
Ovarian cysts
PPTX
BARTHOLINS.pptx
PPTX
management of placenta previa
PPT
adenomyosis
PPT
Female sterlization
PPTX
PPT
DYSMENORRHOEA
PPT
Amenorrhea
PPTX
Abnormal Uterine Bleeding by Dr Kemi Dele
PPTX
Salpingitis
PPTX
Genital tract fistula
Cervical erosion
Amenorrhea
Amenorrhea
Preterm labour
Premenstrual syndrome
Genital tuberculosis
Disorders of menstruation
Ovarian cysts
BARTHOLINS.pptx
management of placenta previa
adenomyosis
Female sterlization
DYSMENORRHOEA
Amenorrhea
Abnormal Uterine Bleeding by Dr Kemi Dele
Salpingitis
Genital tract fistula
Ad

Similar to Dysfunctional uterine bleeding (20)

PDF
Abnormal uterine bleeding
PPT
DUB (uterine bleeding)
PPTX
05. abnormal uterine bleeding etiology and management in gynecology
PPTX
Septic abortion
PDF
AUB for 4th year med.students
PPTX
Final PPT Urinary Tract Infection In Pregnancy -1-1.pptx
PPTX
Disorders of the menstrual cycle 1
PPTX
Menstrual irregularities - Menorrhagia
PDF
Patient preparation before IVF
PPTX
ACUTE ABNORMAL UTERINE BLEEDING
PDF
Management of Female infertility
PDF
Dysfunctional uterine bleeding
PDF
Treatment of OHSS
PPT
Gynaecological emergencies
PPTX
abnormal vaginal bleeding.pptx
PPTX
ANTEPARTUM HEMMORRHAGE - pregnancy complication
PPT
Gynecology 5th year, 4th lecture (Dr. Sindus)
PPT
dr.salama DUB
PPT
Cgd 2
Abnormal uterine bleeding
DUB (uterine bleeding)
05. abnormal uterine bleeding etiology and management in gynecology
Septic abortion
AUB for 4th year med.students
Final PPT Urinary Tract Infection In Pregnancy -1-1.pptx
Disorders of the menstrual cycle 1
Menstrual irregularities - Menorrhagia
Patient preparation before IVF
ACUTE ABNORMAL UTERINE BLEEDING
Management of Female infertility
Dysfunctional uterine bleeding
Treatment of OHSS
Gynaecological emergencies
abnormal vaginal bleeding.pptx
ANTEPARTUM HEMMORRHAGE - pregnancy complication
Gynecology 5th year, 4th lecture (Dr. Sindus)
dr.salama DUB
Cgd 2
Ad

More from Aboubakr Elnashar (20)

PDF
WHAT IS NEW IN ESHRE 2022 AND FIGO 2022 FOR GENERAL GYNAECOLOGIST
PDF
hepatitis B.pdf
PDF
hepatitis c2022.pdf
PDF
Adenomyosis associated infertility
PDF
Endometriosis associated infertility: ESHRE2022
PDF
Adenxal mass guidelines2020
PDF
Aesthetic gynecology controversy
PDF
Hormonal assay in clinical gyn
PDF
FIRST TRIMESTER ANC OF IVF
PDF
Unnecessary investigations in reproductive medicine
PDF
Infertility prevention
PDF
Individualisation of controlled ovarian stimulation
PDF
Female infertility
PDF
Maternal near miss
PDF
THE MANAGEMENT OF SEVERE PET/ECLAMPSIA
PDF
cesarean birth: procedural aspects: NICE2021
PDF
CAESAREAN SCAR DEFECT
PDF
Management of pregnancy of unknown location
PDF
Aerobic Vaginitis
PDF
COVID 19 infection and pregnancy RCOG2021
WHAT IS NEW IN ESHRE 2022 AND FIGO 2022 FOR GENERAL GYNAECOLOGIST
hepatitis B.pdf
hepatitis c2022.pdf
Adenomyosis associated infertility
Endometriosis associated infertility: ESHRE2022
Adenxal mass guidelines2020
Aesthetic gynecology controversy
Hormonal assay in clinical gyn
FIRST TRIMESTER ANC OF IVF
Unnecessary investigations in reproductive medicine
Infertility prevention
Individualisation of controlled ovarian stimulation
Female infertility
Maternal near miss
THE MANAGEMENT OF SEVERE PET/ECLAMPSIA
cesarean birth: procedural aspects: NICE2021
CAESAREAN SCAR DEFECT
Management of pregnancy of unknown location
Aerobic Vaginitis
COVID 19 infection and pregnancy RCOG2021

Recently uploaded (20)

PPTX
CARDIOVASCULAR AND RENAL DRUGS.pptx for health study
PPTX
thio and propofol mechanism and uses.pptx
PPT
neurology Member of Royal College of Physicians (MRCP).ppt
PDF
Forensic Psychology and Its Impact on the Legal System.pdf
PDF
OSCE SERIES - Set 7 ( Questions & Answers ).pdf
PPT
Dermatology for member of royalcollege.ppt
PPTX
HYPERSENSITIVITY REACTIONS - Pathophysiology Notes for Second Year Pharm D St...
PPTX
NUCLEAR-MEDICINE-Copy.pptxbabaabahahahaahha
PPTX
4. Abdominal Trauma 2020.jiuiwhewh2udwepptx
PDF
OSCE Series Set 1 ( Questions & Answers ).pdf
PDF
The_EHRA_Book_of_Interventional Electrophysiology.pdf
PPTX
Vaccines and immunization including cold chain , Open vial policy.pptx
PPT
Infections Member of Royal College of Physicians.ppt
PDF
OSCE SERIES ( Questions & Answers ) - Set 3.pdf
PPTX
Neoplasia III.pptxjhghgjhfj fjfhgfgdfdfsrbvhv
PDF
OSCE Series ( Questions & Answers ) - Set 6.pdf
PPTX
Introduction to Medical Microbiology for 400L Medical Students
PDF
The Digestive System Science Educational Presentation in Dark Orange, Blue, a...
PDF
04 dr. Rahajeng - dr.rahajeng-KOGI XIX 2025-ed1.pdf
PPTX
@K. CLINICAL TRIAL(NEW DRUG DISCOVERY)- KIRTI BHALALA.pptx
CARDIOVASCULAR AND RENAL DRUGS.pptx for health study
thio and propofol mechanism and uses.pptx
neurology Member of Royal College of Physicians (MRCP).ppt
Forensic Psychology and Its Impact on the Legal System.pdf
OSCE SERIES - Set 7 ( Questions & Answers ).pdf
Dermatology for member of royalcollege.ppt
HYPERSENSITIVITY REACTIONS - Pathophysiology Notes for Second Year Pharm D St...
NUCLEAR-MEDICINE-Copy.pptxbabaabahahahaahha
4. Abdominal Trauma 2020.jiuiwhewh2udwepptx
OSCE Series Set 1 ( Questions & Answers ).pdf
The_EHRA_Book_of_Interventional Electrophysiology.pdf
Vaccines and immunization including cold chain , Open vial policy.pptx
Infections Member of Royal College of Physicians.ppt
OSCE SERIES ( Questions & Answers ) - Set 3.pdf
Neoplasia III.pptxjhghgjhfj fjfhgfgdfdfsrbvhv
OSCE Series ( Questions & Answers ) - Set 6.pdf
Introduction to Medical Microbiology for 400L Medical Students
The Digestive System Science Educational Presentation in Dark Orange, Blue, a...
04 dr. Rahajeng - dr.rahajeng-KOGI XIX 2025-ed1.pdf
@K. CLINICAL TRIAL(NEW DRUG DISCOVERY)- KIRTI BHALALA.pptx

Dysfunctional uterine bleeding

  • 1. Dysfunctional uterine bleeding Aboubakr Elnashar Benha university, Egypt Aboubakr Elnashar
  • 2. Define DUB: Any abnormal uterine bleeding in absence of pregnancy, genital tract pathology, or systemic disease Menorrhagia; commonest symptom DUB: 50-60% 15-20% of gynaecological referrals to Hospital Excessive blood loss: >80mL are clinically meaningless If periods are reported as unacceptably heavy. then they are! Aboubakr Elnashar
  • 3. CLINICAL TYPES Polymenorrhoea: frequent (<21 d) menstruation, at regular intervals Menorrhagia: Excessive & / or prolonged menstruation, at regular intervals Metrorrhagia: Excessive & / or prolonged menstruation at irregular intervals. Menometrorrhagia: both. Intermenstual bleeding: episodes of uterine bleeding between regular menstruations Hypomenorrhoea: scanty menstruation. Oligomenorrhea: infrequent menstruation (>35 d) Aboubakr Elnashar
  • 4. Aetiology unknown. Mechanisms 1. Abnormal PG ratios (+ other inflammatory mediators) favoring VD and platelet non- aggregation. 2. Excessive fibrinolysis. 3. Defects in expression/function of matrix metalloproteinases (MMPs), vascular growth factors, and endothelins. 4. Aberrant steroid receptor function. 5. Defects in the endomyometrial junctional zone. Aboubakr Elnashar
  • 5. Diagnosis Symptoms 1. Heavy and/or prolonged vaginal bleeding (with clots and flooding): 2. Irregular, heavy periods usually occur at the extremes of reproductive life (post-menarche and peri-menopausal). 3. ± dysmenorrhoea. 4. Systemic symptoms of anaemia and disruption of life due to bleeding. 5. A smear history and contraceptive use are vital information. Totally irregular bleeding, IMB. or PCB: prompt a search for cervical or endometrial pathology. Aboubakr Elnashar
  • 6. Clinical signs 1. Anaemia. 2. Abdomino-pelvic examination: usually normal. If the uterus is significantly enlarged. fibroids are likely. Aboubakr Elnashar
  • 7. Differential diagnosis 1. Submucous fibroids. 2. Adenomyosis. 3. Endometrial polyps, hyperplasia, or cancer. 4. Very rarely hypothyroidism or coagulation defects. Aboubakr Elnashar
  • 8. Investigations 1. Pregnancy should always be considered and excluded. 2. CBC (Hb + MCV). 3. Not a routine a. Ferritin, TFT s, and clotting screens: investigations-only consider if clinically indicated. b. Cervical smears: not done opportunistically if smear history normal. c. STI screen including Chlamydia. Aboubakr Elnashar
  • 9. Testing for coagulation disorders (von Willebrand’s disease) 1. HMB since menarche adolescents 2. Personal or family history suggesting a coagulation disorder. Prothrombin time, Partial thrmoplastin time, Bleeding time, Platelets, Von Willebrand factor with the ristocetin cofactor assay {the single best screening test for the disease. This prevents false-negative results}  Prolactin & TSH: especially in adolescents Aboubakr Elnashar
  • 10. 4. <45yrs The risk of endometrial pathology is very small: No further investigation: treat and await clinical response. Aboubakr Elnashar
  • 11. 5. If >45yrs risk factors for endometrial disease, or no clinical response: 1. TVS US  endometrial polyps fibroids measuring endometrial thickness. The risk of endometrial pathology with a normal TVS USS is small, but it may be less accurate during menstruation Aboubakr Elnashar
  • 12. 2. Pipelle endometrial biopsy Indication: erratic bleeding in women >45yrs To exclude hyperplasia or cancer Aboubakr Elnashar
  • 13. 3. Hysteroscopy and biopsy • Indication 1. Erratic bleeding in a woman >45yrs if USS reveals focal pathology. e.g. polyp, or is unable to assess the whole endometrium, 2. biopsy is inadequate 3. bleeding is persistent or repeated. Aboubakr Elnashar
  • 14. Management Regular DUB 1. Mirena IUCD •Releases measured doses of levonorgestrel into the endometrial cavity for 5yrs inducing an atrophic endometrium. •Effects: Blood loss dec by up to 90% 30% will be amenorrhoeic at 12mths. major dec in number of hysterectomies. Provides contraception. •Side effects: insertional issues irregular PV bleeding for first 4-6mths (usually abates) progestagenic side effects: rare {minimal systemic absorption}. Aboubakr Elnashar
  • 15. 2. Antifibrinolytics: tranexamic acid •1g tds days 1-4 •40% dec in loss •Safe, non-hormonal, non-contraceptive •Side effects leg cramps minor GI upset •Caution in cardiac disease. The majority of women will respond to medical therapy, especially tranexamic ± mefenamic add. Aboubakr Elnashar
  • 16. 3. NSAIDS: mefenamic acid •500mg tds days 1-5 •20-30% dec in loss •significant dec in dysmenorrhoea •Safe, non-hormonal contraceptive. •Side effects GI upset including ulceration. renal impairment •Caution: Asthmatic CV disease renal impairment peptic ulcer. Aboubakr Elnashar
  • 17. 4. COCP: •20-30% dec loss •improvement in dysmenorrhoea •provides contraception •Side effects BTB Headache Wt gain Aboubakr Elnashar
  • 18. •Contraindications 1. Breast cancer 2. Breast feeding, postpartum less than 1 month 3. Cirrhosis Severe 4. DVT/PE 5. DM: nephropathy, retinopathy, 6. GB disease 7. Headache: Migraine with aura 8. Hypertension 9. Liver tumors: adenoma, malignancy 10.Multiple risk factors for arterial vas Dis 11.Smoking +above 35 y 12.SLE 13.Viral hepatitis: acute 14.Drug interaction: Anticonvulsant, Rifampicin,Aboubakr Elnashar
  • 19. 5. Oral progestagens: no benefit in regular menorrhagia other than-short term continuous treatment to stop bleeding. Aboubakr Elnashar
  • 20. Irregular DUB 1. Mirena IUCD: as above. 2. Tranexamic 3. mefenamic acid useful to dec loss during periods. 4. COCP regulate an irregular cycle safe up to the menopause if no other cardiovascular risk factors. Aboubakr Elnashar
  • 21. 4. Progestagen •Cyclical (days 5-26) •Norethisterone 5mg tds or medroxyprogesterone acetate 5-10 mg tds •Regulates cycle. but little evidence to suggest dec in loss •Side effects Bloating headache. Aboubakr Elnashar
  • 22. 5. further medical treatment Indications 1. First-line therapy has failed 2. Very anaemic women, bleeding continuously. having their life disrupted 3. Cautions or contraindications to surgery. a. GnRH analogues •Achieve amenorrhoea quickly by inducing a medical menopausal state •Side effects vasomotor symptoms •use limited to 6-12mths maximum {bone loss}. Aboubakr Elnashar
  • 23. b. High-dose progestagens: •medroxyprogesterone acetate 10mg tds continuously •induce amenorrhoea. •may be time-limited due to side effects. Danazol and ethamsylate: no longer indicated. Aboubakr Elnashar
  • 24. Surgical management Indications 1. Failure to respond to medical management 2. Women have completed her family Aboubakr Elnashar
  • 25. 1. Endometrial ablation  Destruction of the endometrium down to the basalis layer Effective for most women Methods: 1. Hysteroscopic resection, or rollerball ablation now used much less often {operative complications} 2. New A. Microwave (MEA). B. Thermal balloon (Thermachoice). C. Novasure (electrical impedance). Aboubakr Elnashar
  • 26. Therma Choice: Heating element within the balloon (Neuwirth et al 1994) Aboubakr Elnashar
  • 27. Nova sure: The bipolar radio frequency wire mesh over a triangular frame (Cooper et al 2002) Aboubakr Elnashar
  • 28. Microwave endometrial ablation (Bain et al., 2002) MEA Aboubakr Elnashar
  • 29. Results •less effective if the endometrial cavity is >10cm. •in normal size cavities: 80-90%: significantly improved. 30%: amenorrhoeic. 20%: need a second procedure by 5yrs. Risk: Small bleeding, infection, uterine perforation, and failed procedure. very safe and straight­forward Carried out under GA but may occasionally be done under cervical block. Aboubakr Elnashar
  • 30. 2. Hysterectomy The only guaranteed cure for DUB Compared to ablation higher morbidity longer recovery financial costs Complications Haemorrhage Infection bladder, ureteric, or bowel injury «1%). Death is extremely rare. Long-term satisfaction rates very high and regardless of method most women report improved sexual function Aboubakr Elnashar